Antisense‐mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first‐in‐human randomized, placebo‐controlled trial

AIMS: LDL‐receptor expression is inhibited by the protease proprotein convertase subtilisin/kexin type 9 (PCSK9), which is considered a pharmacological target to reduce LDL‐C concentrations in hypercholesterolaemic patients. We performed a first‐in‐human trial with SPC5001, a locked nucleic acid ant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: van Poelgeest, Eveline P., Hodges, Michael R., Moerland, Matthijs, Tessier, Yann, Levin, Arthur A., Persson, Robert, Lindholm, Marie W., Dumong Erichsen, Kamille, Ørum, Henrik, Cohen, Adam F., Burggraaf, Jacobus
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4693495/
https://ncbi.nlm.nih.gov/pubmed/26261033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12738
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados